Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
24/05/2024 | 22:35 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
24/05/2024 | 22:31 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
24/05/2024 | 22:30 | GlobeNewswire Inc. | Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
18/05/2024 | 01:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
14/05/2024 | 22:25 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
13/05/2024 | 11:00 | GlobeNewswire Inc. | Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
09/05/2024 | 22:11 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
09/05/2024 | 22:01 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
02/05/2024 | 14:00 | GlobeNewswire Inc. | Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
01/05/2024 | 14:01 | GlobeNewswire Inc. | Recursion to Participate in Upcoming Investor Conferences | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
30/04/2024 | 14:00 | GlobeNewswire Inc. | Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
16/04/2024 | 14:00 | GlobeNewswire Inc. | Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
02/04/2024 | 14:00 | GlobeNewswire Inc. | Recursion to Participate in Upcoming Investor Conference | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
26/03/2024 | 13:00 | GlobeNewswire Inc. | Recursion Publishes Annual Environmental, Social and Governance Report | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
11/03/2024 | 09:00 | GlobeNewswire Inc. | Recursion Announces Plans to Open New Office in London | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
01/03/2024 | 20:58 | GlobeNewswire Inc. | Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
29/02/2024 | 14:25 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
27/02/2024 | 22:05 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
20/02/2024 | 13:59 | GlobeNewswire Inc. | Recursion to Host Public L(earnings) Call on February 27 | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
12/02/2024 | 18:21 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
29/01/2024 | 22:00 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
24/01/2024 | 15:00 | GlobeNewswire Inc. | Altitude Lab Startups Raise Over $120M in Capital | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
08/01/2024 | 16:59 | GlobeNewswire Inc. | Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
04/01/2024 | 13:59 | GlobeNewswire Inc. | Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
20/12/2023 | 13:59 | GlobeNewswire Inc. | Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
15/12/2023 | 14:38 | Edgar (US Regulatory) | Form 424B7 - Prospectus [Rule 424(b)(7)] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
09/11/2023 | 15:41 | GlobeNewswire Inc. | Bayer and Recursion Focus Research Collaboration on Oncology | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
09/11/2023 | 14:01 | GlobeNewswire Inc. | Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
09/11/2023 | 13:58 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
05/09/2023 | 13:59 | GlobeNewswire Inc. | Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |